Spots Global Cancer Trial Database for myelodysplastic
Every month we try and update this database with for myelodysplastic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) | NCT00854646 | Acute Myelocyti... Acute Lymphocyt... Chronic Myelocy... Chronic Lymphoc... Myelodysplastic... | ON 01910.Na | 18 Years - | Traws Pharma, Inc. | |
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) | NCT00854646 | Acute Myelocyti... Acute Lymphocyt... Chronic Myelocy... Chronic Lymphoc... Myelodysplastic... | ON 01910.Na | 18 Years - | Traws Pharma, Inc. | |
Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS | NCT04810611 | Myelodysplastic... | MBG453 NIS793 canakinumab | 18 Years - | Novartis | |
Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS) | NCT00867061 | Myelodysplastic... | ON 01910.Na Con... | 18 Years - | Traws Pharma, Inc. | |
Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101) | NCT03016130 | Leukemia Myelodysplastic... | Diet | 18 Years - | University of Florida | |
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) | NCT00854646 | Acute Myelocyti... Acute Lymphocyt... Chronic Myelocy... Chronic Lymphoc... Myelodysplastic... | ON 01910.Na | 18 Years - | Traws Pharma, Inc. | |
A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. | NCT01236144 | Acute Myeloid L... High Risk Myelo... | Plerixafor AC220 Ganetespib | 60 Years - | Cardiff University | |
A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. | NCT01236144 | Acute Myeloid L... High Risk Myelo... | Plerixafor AC220 Ganetespib | 60 Years - | Cardiff University | |
Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101) | NCT03016130 | Leukemia Myelodysplastic... | Diet | 18 Years - | University of Florida |